Cancers | Free Full-Text | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
Ibritumomab tiuxetan
Ibritumomab tiuxetan - Wikipedia
Ibritumomab tiuxetan (Zevalin) - Indications, Dosing, Side effects
Ibritumomab Tiuxetan (Zevalin) Drug Info
SNM: Image of the Year shows radioimmunotherapy's effectiveness against non-Hodgkin's lymphoma
Reference ID: 3366104
111In-ibritumomab tiuxetan, Zevalin
Consent for Y-90 Zevalin Radiation Therapy, #577240
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment | Journal of Nuclear Medicine
Schematic representation of 90 Y-labelled Zevalin, consisting of the... | Download Scientific Diagram
ZEVALIN - ibritumomab tiuxetan Acrotech Biopharma LLC ----------
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma - ScienceDirect
90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | Journal of Nuclear Medicine Technology
Ibritumomab Tiuxetan (Zevalin) Drug Info
The radio-labeled antibody 90 Y-ibritumomab tiuxetan (Zevalin) binds to... | Download Scientific Diagram
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) - The Lancet Oncology
Zevalin: Package Insert - Drugs.com
Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? | Semantic Scholar
Zevalin™ Y-90 Unit Dose Pig | Mirion Technologies (Capintec), Inc.
Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment - The Lancet Oncology
Y-90 Ibritumomab Tiuxetan
Schematic representation of Zevalin ® targeting a lymphoma B-cell with... | Download Scientific Diagram
Ibritumomab tiuxetan | New Drug Approvals
Ibritumomab - Zevalin® - GlobalRPH
Schematic representation of 90 Y-labelled Zevalin, consisting of the... | Download Scientific Diagram
NM Therapies Radiopharm - NMTCB Flashcards | Quizlet
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial - Biology
90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging | Journal of Nuclear Medicine
